Switchable Cas9 Nucleases and Uses Thereof - EP3693461A1

The EPO granted Patent EP3693461A1 for switchable Cas9 nucleases and uses thereof to President and Fellows of Harvard College. The invention, invented by David R. Liu and Johnny Hao Hu, covers controlled gene editing systems. The patent application was published under international patent classification C12N with designations across 39 European states.

Biotechnology companies engaged in gene editing research and development should evaluate whether their technologies fall within the scope of this patent. Parties may need to seek licensing from Harvard or assess potential design-around strategies to avoid infringement claims in designated EPO member states.